Subversive Highlights InterCure's Q4 Estimated Unaudited Results & Provides Update on TSX Listing and Name Change.

TORONTO: SUBVERSIVE ACQUISITION LP (NEO: SVX.U) (OTCQX: SBVRF) ("SVX") (previously Subversive Real Estate Acquisition REIT LP) announced today that InterCure Ltd. (dba Canndoc) (TASE: INCR) ("InterCure"), Israel's leading cannabis company and SVX's intended target for its "Qualifying Transaction" (the "Transaction"), has released its estimated unaudited fourth quarter results for the year ended December 31, 2020 (the "InterCure Press Release"). Highlights include:

NIS NS27 million in fourth quarter revenue, establishing a new quarterly revenue record for InterCure;

Revenue growth of more than 13 times compared to Q4 2019 and more than 3 times compared to InterCure's annual revenue in 2019;

Continued increase in profitability, operating profit and net profit;

Continued growth in market share, due to growing demand for Canndoc's products;

The Q4 growth in revenue and profitability does not include the new operations acquired in January 2021 and commercialization of InterCure's southern facility, the largest and most advanced in Israel, which occurred in 2021.

Attached as Schedule A to this press release is a translated version of the full InterCure Press Release.

As previously announced by SVX on January 25, 2021, the Canndoc investment highlights include:

Proven Business Model - The most profitable company in Israel's growing legal cannabis market with a Q4 2020 expected EBITDA annualized run rate of greater than US$10 million and positive free cash flow

First Mover Advantage - Significant share of medical market, which grew 40% in 2020; First company to import medical grade cannabis to Israel; Positioned to capitalize on the legalization of recreational cannabis

Progressive Operational Platform - Highly profitable, vertically integrated medical cannabis platform

Key Partnerships - Canndoc's exclusive partnerships with leading cannabis brands and suppliers include Cookies, Charlotte's Web, Aphria, Tilray, Organigram, and more

Robust Balance Sheet to Support Expansion - Cash to drive significant expansion organically and through strategic M&A; Expected expansion of cultivation to over 90 tons per year; Expected to open four additional pharmacies in 2021

...